Browse studies

Find your next paid study

600 recruiting studies matching your filters

PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (AR…

Prostate Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06780670

Phase 3

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prosta…

Oligometastatic Prostate Cancer (OMPC)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT05939414

Phase 3

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (d…

Metastatic Castration-resistant Prostate Cancer

Estimated

~$10 – $7,500

AmgenNCT07213674

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people …

Prostate Cancer

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02594202

Phase 1

An Open-label, Multi-center, First in Human Phase I Global Dose Escalation and Expansion Study of INR731 Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of IN…

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07570979

Phase 1

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properti…

Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07006727

A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL

Background: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their …

Prostate CancerBiochemically Recurrent

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT05588128

Phase 3

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus and…

Prostate Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06855277

Protoacoustic Imaging for 3D Mapping the Bragg Peak in Real Time During Proton Therapy (PROTEUS)

The purpose of this study is to test a new imaging technology called radioacoustic imaging (RAI) that may help doctors see where radiation is being delivered d…

Proton TherapyRadiation Therapy, Secondary Skin ReactionsLiver Cancer+1 more

Estimated

~$10 – $750

University of OklahomaNCT07832617

Phase 2

A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) trea…

High-Risk Localized Prostate Cancer

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07550517

Observational

CV CARE: CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients

This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting an…

Prostate CancerCardiovascular Diseases

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06202820

Phase 2

A Prospective Phase 2/3, Multicenter, Open Label Study of [68Ga]- LNTH2401 PET/CT Imaging in Participants With Prostate Cancer: Phase 2 Dose Optimization in Either Newly Diagnosed or Biochemically Recurrent Prostate Cancer and Phase 3 Diagnostic Performance in Participants Who Are Newly Diagnosed and Have at Least High Risk or Suspected Metastatic Disease and Planning to Undergo Radical Prostatectomy Plus Pelvic Lymph Node Dissection (SPARROW)

This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 …

Prostate Cancer

Estimated

~$10 – $8,750

Lantheus Medical ImagingNCT07831824